Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Assets (2017 - 2025)

Crinetics Pharmaceuticals has reported Other Non-Current Assets over the past 9 years, most recently at $22.3 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $22.3 million for Q4 2025, up 689.22% from a year ago — trailing twelve months through Dec 2025 was $22.3 million (up 689.22% YoY), and the annual figure for FY2025 was $22.3 million, up 689.22%.
  • Other Non-Current Assets for Q4 2025 was $22.3 million at Crinetics Pharmaceuticals, up from $18.4 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for CRNX hit a ceiling of $22.3 million in Q4 2025 and a floor of $500000.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $1.3 million (2022), compared with a mean of $4.4 million.
  • Biggest five-year swings in Other Non-Current Assets: decreased 0.08% in 2023 and later soared 1317.85% in 2025.
  • Crinetics Pharmaceuticals' Other Non-Current Assets stood at $500000.0 in 2021, then soared by 160.2% to $1.3 million in 2022, then fell by 0.08% to $1.3 million in 2023, then surged by 117.62% to $2.8 million in 2024, then surged by 689.22% to $22.3 million in 2025.
  • The last three reported values for Other Non-Current Assets were $22.3 million (Q4 2025), $18.4 million (Q3 2025), and $14.9 million (Q2 2025) per Business Quant data.